<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01098591</url>
  </required_header>
  <id_info>
    <org_study_id>MUW - Meta</org_study_id>
    <nct_id>NCT01098591</nct_id>
  </id_info>
  <brief_title>Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE</brief_title>
  <acronym>ACCRUE</acronym>
  <official_title>Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VZW Cardiovascular Research Center Aalst</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Military Medical Academy, Belgrade, Serbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novosibirsk Scientific Research Institute for Circulatory Pathology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asklepios Kliniken Hamburg GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Debrecen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Targu Mures, Romania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Clinic for Cardiology, Skopje, Republic of Macedonia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State Health Center, Hungary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minneapolis Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinik Hirslanden, Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Numerous human cardiac stem cell studies have been published, including relatively small
      number of patients. Meta-analysis of randomized trials have reported safety and a 3-6%
      increase in global left ventricular performance after intracoronary stem cell therapy in
      patients with acute myocardial infarction. Since most of the studies used different type of
      stem cells, delivery modes, and patient population, the results are heterogenous, therefore
      the comparison of the results is biased regarding generalizable conclusions about the effect
      of treatment. The present comparative meta-analysis is based on individual patient data, and
      gathers and pools the raw data, and analyzes the clinical outcome, safety and efficacy of the
      cardiac stem cell therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Background: Many clinical trials and meta-analyses presented moderate but significant
           improvement of the left ventricular ejection fraction (LVEF) after intracoronary
           autologous bone-marrow (BM) or peripheral blood origin stem cells transfer. However, it
           remains controversial, whether this beneficial effects is comparable with the
           intramyocardial delivery of the stem cells, or could be maintained during moderate and
           long term follow-up. The BOOST trial suggested that cardiac stem cell therapy did not
           improve LVEF at 5-year follow-up. By contrast, BALANCE study showed a long sustained
           benefit of BM-stem cells treatment. Due to these divergent outcomes of the presented
           trials, the aim of the present meta-analysis is to compare the safety and effectiveness
           of the cardiac stem cell therapy in different patient population, delivery mode and cell
           type, to find out, which patients with which therapy mode can have the greatest benefit
           from cardiac stem cell therapy.

        -  Study design: individual patient data meta-analysis

        -  Data sources: European Centre performing human cardiac stem cell therapy have been
           contacted calling for participation.

        -  Methods: Individual data gathering and entering into the database for a pooled analysis.
           The meta-analysis will be done in line with recommendation from the Cochrane
           Collaboration and the Quality of Reporting of Meta-analyses guidelines with Review
           Manager 5.0. Fixed-effect model will be used.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from occurrence of major adverse cardiac and cerebrovascular events (MACCE), including all-cause death, re-infarction, revascularization and stroke</measure>
    <time_frame>12 months</time_frame>
    <description>MACCE is defined as all-cause death, re-infarction, revascularization and stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hard clinical end point</measure>
    <time_frame>12 months</time_frame>
    <description>all-cause death, re-infarction and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in end-diastolic volume</measure>
    <time_frame>12 months</time_frame>
    <description>End-diastolic volume is an index of ventricular remodeling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in end-systolic volume</measure>
    <time_frame>12 months</time_frame>
    <description>Index of ventricular systolic performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ejection fraction</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement of systolic cardiac function after cell therapy</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Myocardial infarction</arm_group_label>
    <description>Patients with post-myocardial infarction receiving cell therapy either intracoronarily or intramyocardial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ischemic cardiomyopathy</arm_group_label>
    <description>Patients with ischemic cardiomyopathy treated with cell therapy either intracoronarily or intramyocardial</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cell therapy</intervention_name>
    <arm_group_label>Myocardial infarction</arm_group_label>
    <arm_group_label>Ischemic cardiomyopathy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with cell-based cardiac therapy at one of the participating centers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient included in one of the registered cell-based cardiac therapy of the
             participating center

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariann Gyongyosi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariann Gyongyosi, MD</last_name>
    <email>mariann.gyongyosi@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariann Gyöngyösi, MD</last_name>
      <email>mariann.gyongyosi@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Mariann Gyöngyösi</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://circres.ahajournals.org/content/early/2015/02/19/CIRCRESAHA.116.304346.long</url>
    <description>Publication</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2010</study_first_submitted>
  <study_first_submitted_qc>April 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2010</study_first_posted>
  <last_update_submitted>March 1, 2015</last_update_submitted>
  <last_update_submitted_qc>March 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Mariann Gyongyosi</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>meta-analysis</keyword>
  <keyword>stem cell</keyword>
  <keyword>cardiac</keyword>
  <keyword>remodeling</keyword>
  <keyword>MESS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

